# EDGAR Filing Document

**Accession Number:** 0002117529
**File Stem:** 0001575872-26-000104
**Filing Date:** 2026-3
**Character Count:** 14356
**Document Hash:** 83db38e12fde3ede4951bd482a303c52
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001575872-26-000104.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001575872-26-000104

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coya Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001835022
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93853
- **FILM NUMBER:** 26747168

**BUSINESS ADDRESS:**
- **STREET 1:** 12645 MEMORIAL DR., SUITE F1 #305
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77024
- **BUSINESS PHONE:** 650.739.3939

**MAIL ADDRESS:**
- **STREET 1:** 12645 MEMORIAL DR., SUITE F1 #305
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77024
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dr. Reddy's Laboratories, Inc.
- **CENTRAL INDEX KEY:** 0002117529

**ORGANIZATION NAME:**
- **EIN:** 223181573
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 600 COLLEGE ROAD EAST
- **STREET 2:** SUITE 4000
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 609-375-9900

**MAIL ADDRESS:**
- **STREET 1:** 600 COLLEGE ROAD EAST
- **STREET 2:** SUITE 4000
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Coya Therapeutics, Inc.

**Title of Class of Securities:** Common Stock, $0.0001 par value per share

**CUSIP Number:** 22407B108

**Date of Event Which Requires Filing of this Statement:** 01/30/2026

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Dr. Reddy's Laboratories, Inc. | Names of Reporting Persons<br>Dr. Reddy's Laboratories, Inc. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>NJ | Citizenship or Place of Organization<br>NJ |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2272727.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2272727.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2272727.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2272727.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.7% | Percent of Class Represented by Amount in Row (9)<br>9.7% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q ("Form 10-Q") filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.

---

| 1. | Names of Reporting Persons<br>Dr. Reddy's Laboratories SA | Names of Reporting Persons<br>Dr. Reddy's Laboratories SA |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>V8 | Citizenship or Place of Organization<br>V8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2272727.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2272727.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2272727.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2272727.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.7% | Percent of Class Represented by Amount in Row (9)<br>9.7% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc.

Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.

---

| 1. | Names of Reporting Persons<br>Dr. Reddy's Laboratories Limited | Names of Reporting Persons<br>Dr. Reddy's Laboratories Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>K7 | Citizenship or Place of Organization<br>K7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2272727.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2272727.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2272727.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2272727.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.7% | Percent of Class Represented by Amount in Row (9)<br>9.7% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc.

Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.

---

**Item 1(a). Name of Issuer:**
Coya Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
5850 San Felipe St., Suite 500, Houston, TX 77057

**Item 2(a). Name of Person Filing:**
Dr. Reddy's Laboratories, Inc.

Dr. Reddy's Laboratories SA

Dr. Reddy's Laboratories Limited

**Item 2(b). Address of Principal Business Office:**
Dr. Reddy's Laboratories, Inc. - 600 College Road East, Suite 4000, Princeton, NJ 08540

Dr. Reddy's Laboratories SA - Grosspeter Tower Grosspeteranlage 294052 Basel, Switzerland

Dr. Reddy's Laboratories Limited - 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India

**Item 2(c). Citizenship:**
Dr. Reddy's Laboratories, Inc. - New Jersey

Dr. Reddy's Laboratories SA - Switzerland

Dr. Reddy's Laboratories Limited - Republic of India

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**Item 2(e). CUSIP Number:**
22407B108

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Dr. Reddy's Laboratories, Inc. is the record owner of 2,272,727 shares of Common Stock of the Issuer. Dr. Reddy's Laboratories, Inc. is a wholly-owned subsidiary of Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories SA is a wholly-own subsidiary of Dr. Reddy's Laboratories Limited. Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories, Inc. may be deemed to beneficially own these securities.

**(b) Percent of class:**

9.7%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Dr. Reddy's Laboratories, Inc. - 2,272,727
Dr. Reddy's Laboratories SA - 2,272,727
Dr. Reddy's Laboratories Limited - 2,272,727

**(ii) Shared power to vote or to direct the vote:**

Dr. Reddy's Laboratories, Inc. - None
Dr. Reddy's Laboratories SA - None
Dr. Reddy's Laboratories Limited - None

**(iii) Sole power to dispose or to direct the disposition of:**

Dr. Reddy's Laboratories, Inc. - 2,272,727
Dr. Reddy's Laboratories SA - 2,272,727
Dr. Reddy's Laboratories Limited - 2,272,727

**(iv) Shared power to dispose or to direct the disposition of:**

Dr. Reddy's Laboratories, Inc. - None
Dr. Reddy's Laboratories SA - None
Dr. Reddy's Laboratories Limited - None

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Dr. Reddy's Laboratories, Inc.**

**Date:** 03/12/2026

**By:** /s/ Stephen Peterson

**Name & Title:** Vice President, Head of Finance NAG

**Dr. Reddy's Laboratories SA**

**Date:** 03/12/2026

**By:** /s/ Sameer Natu

**Name & Title:** Senior Director - Finance

**Dr. Reddy's Laboratories Limited**

**Date:** 03/12/2026

**By:** /s/ K Randhir Singh

**Name & Title:** Company Secretary and Compliance Officer